



Date: 16 April 2026

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi

SUBJECT: EXTRACT OF BOARD MEETING - DISCLOSURE OF MATERIAL INFORMATION

Dear Sir,

This is to inform that the Board of Directors of the Company in its meeting held on 16 Apr 2026, has approved a comprehensive strategic transformation to reposition the Company as a healthcare focused business with an initial emphasis on pharmaceutical licensing, distribution and trading.

This initiative represents a significant shift towards a high growth and resilient sector, characterized by strong demand fundamentals and scalable revenue potential.

The Board has discussed and approved the following key matters:

(1) PROPOSED AMENDMENT OF OBJECT CLAUSE ALONG WITH CHANGE OF NAME:

Alteration of the Memorandum and Articles of Association to enable operations across pharmaceuticals, healthcare and allied sectors, providing a platform for long term expansion as well as rename the company to reflect its new line of healthcare business.

(2) CHANGE OF REGISTERED OFFICE:

Relocation of the registered office from the Province of Sindh to the Province of Punjab, aligning the Company's legal base with its operational focus.

(3) INCREASE IN AUTHORIZED CAPITAL:

Enhancement of authorized share capital to the PKR 800 million to support future capital raising initiatives and working capital requirements.

(4) REGULATORY LICENSING:

Initiation of the process to obtain necessary and relevant licenses from DRAP for enabling entry into the pharmaceutical supply chain, subject to the completion of proposed amendments by the concerned regulators and shareholders of the company.

(5) STRATEGIC EXPANSION:

Authorization to establish domestic and international subsidiaries/SPVs and to pursue strategic partnerships including distribution arrangements and joint ventures with local and international pharmaceutical operators.

The Board noted that the adoption of a distribution led entry strategy is expected to enable rapid market entry with relatively low capital intensity allowing the Company to initiate revenue generating operations in the near term, while building a scalable presence within the pharmaceutical ecosystem.

Execution of the above strategy is targeted within a 90 - 120 days timeline, positioning the Company to transition into an active and revenue generating healthcare business with the potential to materially enhance its scale, earnings profile and market positioning.

The Board has also approved the convening of an Extraordinary General Meeting (EOGM) to seek shareholder's approval for the aforementioned matters, in accordance with applicable laws and regulations.

The above information is being disseminated in compliance with Section 96 of the Securities Act, 2015 and Clause 5.6.1(a) of the PSX Rule Book.

You may please inform the TRE Certificate Holders of the Exchange accordingly.

Yours faithfully,

For and on behalf of
SG Power Limited



Maria Qadeer
Company Secretary